From the EAS:* frequent questions and responses on the 2022 lipoprotein(a) consensus statement of the European Atherosclerosis Society

In 2022 the European Atherosclerosis Society (EAS) published a new consensus statement on lipoprotein(a) (Lp[a)] in atherosclerotic cardiovascular disease (ASCVD) and aortic stenosis [1]. There is now extensive evidence, especially from epidemiology and genetics, strongly supporting a causal association of high Lp(a) with ASCVD outcomes [2,3] and aortic valve stenosis [4], which is driving the development of novel mRNA-targeted therapies that specifically lower Lp(a) > 90% [[5], [6], [7]]. Ongoing randomized clinical trials are testing whether lowering Lp(a) reduces cardiovascular events.

Some argue that measuring Lp(a) is not relevant given the lack of approved specific treatment options. However, the 2022 EAS consensus statement recommends that Lp(a) measurement is an important pillar of comprehensive ASCVD risk evaluation, and that global risk may be underestimated substantially in individuals with high or very high Lp(a) concentrations. The statement provides a clinical framework for personalizing the management of high Lp(a) to reduce ASCVD risk with currently available therapies [1].

This document addresses 30 of the most frequently asked questions about Lp(a) (Fig. 1), providing both a short answer and more detail to each question.

留言 (0)

沒有登入
gif